Join
Live feed
·
PRReleasevia Quantisnow
Ascentage Pharma Group International logo

Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

ByQuantisnow·Wall Street's wire, on your screen.
AAPG· Ascentage Pharma Group International
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AAPG (Ascentage Pharma Group International) and more on Quantisnow.